Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,301 Shares of Stock

August 7, 2026 by InsiderTrades.com

Key Points

Castle Biosciences insider Derek Maetzold sold 20,356 shares for approximately $633,275 at an average price of $31.11, reducing his direct ownership by 48.66%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan.
The company’s latest quarterly results exceeded expectations, with revenue of $99.86 million versus the $86.23 million consensus estimate and a per-share loss of $0.07 compared with the expected $0.41 loss.
Castle Biosciences traded near $30.47, while analysts maintained a generally positive outlook: the stock has a “Moderate Buy” consensus rating and a $42 average price target.

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 1,301 shares of the firm's stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $38.39, for a total transaction of $49,945.39. Following the completion of the transaction, the insider owned 77,694 shares in the company, valued at $2,982,672.66. This represents a 1.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 0.2%

NASDAQ:CSTL opened at $30.47 on Friday. The company has a fifty day moving average of $23.55 and a 200 day moving average of $26.16. Castle Biosciences, Inc. has a 52 week low of $17.72 and a 52 week high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $930.86 million, a P/E ratio of -46.17 and a beta of 0.98.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. The business had revenue of $99.86 million during the quarter, compared to analysts' expectations of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. On average, research analysts predict that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CSTL. Global Retirement Partners LLC purchased a new stake in Castle Biosciences in the second quarter worth about $26,000. Federated Hermes Inc. purchased a new position in Castle Biosciences during the fourth quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new position in Castle Biosciences during the fourth quarter valued at $35,000. Jones Financial Companies Lllp boosted its holdings in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company's stock worth $54,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company's stock worth $55,000 after acquiring an additional 297 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences News Summary

Here are the key news stories impacting Castle Biosciences this week:

Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and suggests meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
Positive Sentiment: Castle Biosciences’ latest quarterly results significantly exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the per-share loss was $0.07 compared with the expected $0.41 loss. The company remains unprofitable, but the revenue growth and narrower loss reinforce the improving operating outlook.
Neutral Sentiment: Institutional investors and hedge funds continue to hold approximately 92.6% of Castle Biosciences’ outstanding shares. Recent position increases by firms including AQR Capital Management, Amundi and Legal & General may provide some institutional support, although these ownership changes are not necessarily a near-term catalyst.
Negative Sentiment: Several insiders reported sizable stock sales. Derek J. Maetzold sold 39,016 shares for roughly $1.21 million in transactions on August 4–5, while COO Kristen Oelschlager sold 8,586 shares for about $256,000. Tobin W. Juvenal also disclosed a 1,730-share sale worth approximately $49,000. The sales reduce insider ownership and could weigh on sentiment after the stock’s recent advance, although the transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal. Castle Biosciences insider sales filing

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Roth Capital began coverage on Castle Biosciences in a report on Wednesday, June 24th. They set a "buy" rating and a $40.00 price target on the stock. BTIG Research upped their target price on Castle Biosciences from $40.00 to $44.00 and gave the company a "buy" rating in a report on Monday. Canaccord Genuity Group cut their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, April 20th. Weiss Ratings upgraded shares of Castle Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, July 31st. Finally, KeyCorp set a $35.00 target price on shares of Castle Biosciences in a research note on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $42.00.

Read Our Latest Research Report on CSTL

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.